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Regional myocardial echo contrast appearance-disap-
pearance after intracoronary contrast agent injection
was examined with computerized two-dimensional con-
trast echocardiography in eight open chest dogs during
successive variation of the coronary blood supply. A new
sonication method applied to dextrose 50% produced an
echo contrast agent with a microbubble size of 12 ± 6
p, (mean ± standard deviation), and 1 cc of this agent
was injected into a coronary artery during the echocar-
diographic study of the left ventricle. Left anterior de-
scending or circumflex coronary artery flow, measured
by electromagnetic flowmeter, was successively reduced
up to 90% with an extravascular hydraulic occluder, or
else increased 40 to 60% through intravenous dipyri-
damole infusion (7 to 10 p,g/kg pcr min). The corre-
sponding myocardial echo time-intensity curves were
analyzed for each of 12 segments of a midventricular
short-axis cross section.
Several potential indexesof myocardial perfusion were
derived: peak echo contrast intensity, time from echo
contrast appearance to peak intensity, half-life of echo
Although recent studies described by Armstrong et al. (I)
and Tei et al. (2) demonstrated the use of contrast two-
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contrast decay phase (T 1/2) and total duration of contrast
appearance-disappearance. Except for peak intensity,
all of these indexes provided significant (p < 0.05) dif-
ferentiation between control coronary flow (66 ± 17
ml/min) and greater than 50% flow reductions (26 ± 6
ml/min) or hyperemia (115 ± 17 ml/min). Half-life val-
ues were 5.2 ± 0.3 seconds for the control state, 9 ± 2
seconds for the reduced coronary flowand 2 ± 2 seconds
for dipyridamole hyperemia. Compared with an echo
contrast-delineated circumferential extent of 5.6 ± 1.4
myocardial segments subserved from the site of the coro-
nary occluder, greater than 50% flow reduction signif-
icantly decreased contrast disappearance T V2 in 3.7 ±
1.7 segments versus decreased systolic wall thickening
in 6.6 ± 1.4 segments. T 1/2 for the central ischemic zone
correlated moderately with coronary flow (r = 0.56, P
< 0.05).
It is concluded that myocardial contrast two-dimen-
sional echocardiography, using small microbubbles as
the agent, can identify a primary perfusion defect and
may permit characterization of myocardial blood supply.
dimensional echocardiography for delineation of underper-
fused myocardium, attempts to quantitate the degree of per-
fusion by studying myocardial contrast appearance-disap-
pearance have not as yet been successful. Studies of the
extent of perfusion defects generally employed agents con-
taining relatively large microbubbles which potentially ob-
struct myocardial capillaries (3). Echo contrast character-
ization of myocardial blood flow levels appears to depend
on agents with significantly smaller microbubbles and im-
proved understanding of the physics of the contrast-ultra-
sound processes.
Our research laboratory has investigated a number of
available solutions to specially prepare echo contrast agents
containing small microbubbles that might be compatible
with passage through the capillary circulation (3). Further-
more, we employed echographic equipment which featured
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logarithmic linear echo gray scale assignment to more quan-
titatively display changes in myocardial echo intensities (4,5).
The present two-dimensional myocardial contrast echocar-
diographic study attempts to relate changes in echo ampli-
tudes after intracoronary echo contrast injections at several
levels of coronary flow to simultaneous electromagnetic flow
measurements.
Methods
Animal preparation. The study was performed in eight
mongrel dogs, each weighing 25 to 35 kg. Each dog was
placed on a special table to facilitate echocardiographic and
fluoroscopic studies (6). Anesthesia was induced using in-
travenous sodium pentobarbital (35 mg/kg), 20 minutes after
premedication with intramuscular morphine sulfate (I mg/kg).
Respiration was maintained with a Harvard respirator. Hep-
arin (1,000 international units) was given before instru-
mentation and followed by 3,000 international units every
3 hours. Supplemental pentobarbital was also administered
when required. Normal saline solution was infused through-
out the experiment at a rate of 150 mllhour.
The chest was opened by incision in the fourth left in-
tercostal space and the opened pericardial sac was deployed
as a cradle support for the exposed heart. The left anterior
descending or the left circumflex coronary artery was dis-
sected and a calibrated external flow probe was placed around
the anterior descending branch in one dog and the circumflex
branch of the left coronary artery in the remaining seven
dogs. Electromagnetic flow measurements were performed
with a Micron Instruments RC 1000 flow meter. A hydraulic
occluder was positioned immediately distal to the flow probe
to permit variation of the coronary artery flow.
An 8F catheter was placed in the aortic root and a 7F
catheter was advanced into the left ventricle for measure-
ments of aortic and left ventricular pressures using Statham
P23 Db transducers. The chest was then reclosed, and the
extravascular hydraulic coronary artery manipulation was
performed from the outside. The animal's condition was
allowed to stabilize before continuation of the experimental
protocol. The electrocardiogram, left ventricular and aortic
pressures and coronary artery flow were simultaneously re-
corded on an Electronics for Medicine recorder.
Echocardiographicexamination. Two-dimensionalecho-
cardiograms were obtained as described previously (6) using
a 3MHz transducer (Advanced Technology Laboratories,
Mk3OOLx). The dog was positioned on its right side on a
special table with a cutout to allow the echographic trans-
ducer to be directed upward against the right side of the
chest, using the point of maximal cardiac pulsation as a
reference. One long-axis and five short-axis images of the
left ventricle were obtained. All measurements were re-
corded on videotape (VHS) and analyzed after completion
of the study. During all echocardiographic examinations,
special attention was paid to avoid changes after an optimal
gain setting was selected before the echo contrast injections.
The echo images of left ventricular myocardium were ob-
tained using specially developed equipment that displayed
myocardial gray scale in a loglinear fashion to facilitate
digitizing procedures and analysis by computer videoden-
sitometry. Details of this system have been described else-
where (7),
Echo contrast agent. Before intracoronary injections,
8 cc of 50% dextrose in water was sonicated for 30 seconds
at 20,000 Hz, producing a stable echo contrast agent con-
taining microbubbles of 12 ± 6 p, diameters. The ability
of this and similar agents to traverse the microcapillary
circulation has been studied separately in the cat mesentery
(3) and in the dog with pulmonary contrast injections (6).
After preparation of the contrast, 1 cc of sonicated 50%
dextrose was injected selectively into the left anterior de-
scending or circumflex coronary artery to outline the area
of echo contrast enhancement in the zone subserved by that
artery, and thus to determine a myocardial perfusion zone
(1,2). Thereafter, duplicate injections of I cc sonicated 50%
dextrose were made into the left main coronary artery to
enhance with echo contrast the entire myocardium viewed
in the left ventricular short-axis cross section studied. The
appearance-disappearance of echo contrast was continu-
ously recorded and analyzed by the computer-aided two-
dimensional echographic method (7).
Study protocol. Duplicate injections of echo contrast (I
cc) were first carried out in a control state (3). Coronary
flow was then reduced incrementally to 75,50,25, and 10%
of the control level, and duplicate coronary artery injections
were performed for each degree of flow reduction. After
completion of this phase of the study, the coronary artery
occluder was released, permitting return of normal coronary
flow. Dipyridamole (7 to 10 M-g/kg per min) was adminis-
tered intravenously to dilate the coronary bed and study
echo contrast images in a hyperemic state. The extracoron-
ary hydraulic occluder was applied to obtain two hyperemic
flow states (140 and 160% of control). Echo images were
recorded continuously in a midpapillary short-axis cross
section, before, during and after intracoronary echo contrast
injection, until it completely disappeared from the myocar-
dium. Heart rate, arterial pressure an epicardial flow were
also recorded continuously. The level of coronary artery
flow just before echo contrast injection was used for cor-
relative analysis.
All animals were sacrificed directly after the experiment
by an intravenous injection of 10 cc of potassium chloride.
Analysis of two-dimensional echocardiograms. Two-
dimensional echocardiograms of the midpapillary short-axis
cross section of the left ventricle (in the control state and
at various levels of coronary flow) were analyzed first before
any echo contrast enhancement. The epicardial and endo-
cardial interfaces were manually traced using a previously
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described method (8), at both end-diastole (peak of QRS)
and end-systole (smallest left ventricular section area).
Thereafter, the outlines were digitized into our computer
system, which automatically divided the cross section into
twelve 30° segments (7,8). Standardized subdivision was
achieved by designating for reference the junction between
the anterior wall endocardium and the anterior papillary
muscle, and constructingan indexingline betweenthis point
and the center of gravity of the epicardial outline.
Similar images with intracoronary echo contrast-induced
myocardial enhancement were thereafter digitized into the
echographic computer system for calculation and construc-
tion of myocardial echo contrast time-intensitycurves. End-
Figure 1. Control echo contrast time-activity curve. A, Atcontrol
coronary artery flow (66 ± 17 mllmin), demonstrating a short
intensity disappearance half-life (approximately 5 seconds). B,
Schematic ofecho contrast time-intensity curve, indicating several
portions of the curve which might be used to characterize myo-
cardial blood flow: a = peak intensity; b = time of echo contrast
appearance topeak intensity (seconds); c = half-life ofrapid decay
phase (seconds); d = half-life of overall decay phase (seconds);
e = total duration ofecho contrast time-intensity curve (seconds);
f = half-life of curve upstroke (seconds).
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diastolic echographic frames were used (7) for the curve
construction, using a cineloop display of comparable echo
contrast images. A control echo contrast intensity appear-
ance-disappearance curve for a myocardial segment is il-
lustrated in Figure lA, and the type of information sought
through analysis is indicated in a generalized schematic in
Figure lB. Echo intensity was measured as mean pixel
brightness for each of the 12 myocardial segments of the
short-axis cross section, and segment to segment brightness
variation was plotted for each frame and displayed above
the digitized and subdivided contrast two-dimensional echo
image(Fig. 2). The procedurewas repeated for every degree
of coronary flow studied, and a T '12 value (T '12 = In 2/k,
where In = natural logarithm and k = exponential decay
rate) was calculated from the decay phase of the curve (after
background subtraction), usinga monoexponentialleast square
fit, as described previously (7). Peak intensity, appearance
to peak intensity, total curve duration and upstroke half-life
were also calculated (Fig. 18). Whenever the curves ex-
hibited two componentsduring its decayphase(for example,
Fig. IA), T '12 (seconds) was calculated for the initial fast
portion of the curve.
Wall thickness calculation. To provide comparison be-
tween extent of myocardial zones of reduced blood flow
versus reduced contractions, wall thickness was measured
as the mean distance between the epicardial and endocardial
outlines, averagedover fiveconsecutive beats. Systolic wall
Figure 2. Digitized two-dimensional echographic image during
echo contrast enhancement. Endo- and epicardial outlines of an
end-diastolic short-axis left ventricular cross section are drawn and
an internal landmark (anterior papillary muscle [APM]) is used
for referencing and indexing of standardized subdivision into 12
segments. The mean pixel brightness for each of the segments is
determined and displayed (top).
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thickening (%), an index of regional myocardial function
(8) of each of the segments, was calculated as:
End-systolic wall thickness - End-diastolic wall thickness
---"----------------- x 100.
End-diastolic wall thickness
Variability of measurements. To test interobserver
variability of myocardial contrast two-dimensional echo-
graphic T Yz measurements, two observers generated the
time-intensity curves after the digitizing procedure. Intraob-
server variability was assessed by a single observer exam-
ining the same digitized images on two separate occasions,
5 days apart. Inter- and intraobserver variability was tested
in 60 segments in eight dogs. Linear regression analysis
was performed and the standard error of estimate calculated.
Injection to injection variability of T Yz was also calculated
for 30 segments and IO duplicate injections in the eight
dogs.
Statistical analysis. The statistical significance of mea-
surements was analyzed using Student's t test.
Results
Coronary artery flow. Sonicated 50% dextrose (I cc)
injected in the control state resulted in significant coronary
artery hyperemia reaching a peak in 9 ± 4 seconds. The
coronary artery flow increased from 66 ± I7 to 100 ± 22
mllmin (probability [p] < 0.05), after a brief initial decrease
(28 ± II mllmin) lasting 2 ± I seconds (Table I). The
hyperemic response due to injection of the echo contrast
was accompanied by a brief decrease in systolic blood pres-
sure from 112.5 ± 12 to 100 ± 1 mm Hg (p < 0.05) over
a period of 8 ± 4 seconds (Fig. 3, Table I). Hyperemic
response was absent and there were no hemodynamic changes
due to the contrast agent when coronary artery flow was
reducedby more than 50%. At hyperemic flowlevels produced
by intravenous dipyridamole, echo contrast-induced changes
in coronary flow were generally small (15 ± 5%). Table I
also indicates hemodynamic and electrocardiographic changes
when coronary artery flow was reduced by more than 50%
(ischemia) or altered by intravenous dipyridamole. It is ap-
parent that systemic arterial pressure was reduced and heart
rate increased during ischemia and systemic hyperemia in-
duced by dipyridamole.
Echo disappearance half-life (TYz) during ischemia
and hyperemia. Table 2 lists the segment to segment vari-
ation of the computed echo disappearance half-life (T Yz)
corresponding with control coronary artery flow. Averaging
data for all the segments of the short-axis cross section,
T Yz was 5.2 ± 0.3 seconds, with individual segment T Yz
values varying from 4.6 ± 1.0 to 5.6 ± 1.0 seconds. An
abnormal T Yz value for a particular segment was defined
as a value outside the ± 2 standard deviation band around
the normal mean values.
Table 3 shows results for each of the indexes derived
from the computed echo contrast time-intensity curves. Data
are presented for control coronary artery flow level (66 ±
17 mllmin), for ischemia induced by coronary constrictions
causing flow reduction of 50% or more (26 ± 6 mllmin)
and for hyperemia induced by intravenous dipyridamole
(115 ± 17 mllmin). It is evident that all the selected indexes,
including the curve decay myocardial echo contrast disap-
pearance half-life T Yz, provided a significant separation
between ischemia and control. All indexes except time to
peak also provided significant differentiation between di-
pyridamole-induced hyperemia and control.
Figure 4 shows a plot of T Yz values derived for the
center (two segments) of the perfusion zone at various de-
grees of coronary artery flow. It is apparent that significant
coronary artery flow reduction caused an increase in T 1/2;
however, variability of the T Yz measurements is substantial,
particularly at the more severe degrees of coronary flow
reduction. There was a weak correlation between echo con-
trast T Yz and coronary artery flow (r = 0.56, P < 0.05).
Wall thickening during ischemia. The number of seg-
ments in the two-dimensional echocardiographic mid left
ECHO CONTRAST
TIME INTENSITY CURVE
Figure 3. Simultaneous registration of aortic pres-
sure (AoP), coronary artery flow (EM FLOW).
electrocardiogram (ECG) and superimposed myo-
cardial echo contrast time-intensity curve derived
with sonicated dextrose 50% as intracoronary echo
contrast agent (microbubble size = 12 ± 6 J-t).
Contrast appearance-disappearance dynamics, from
which echo contrast indexes are derived. decrease
within the earliest postinjection response, reflecting
an initial reduction in coronary artery flow before
the subsequent development of hyperemia.
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Table 1. Coronary Flow and Hemodynamic and Regional Functional Changes Due to
Intracoronary Injection of Sonicated 50% Dextrose
1223
Coronary flow (ml/niin)
Preinjection
Postinjection
Minimum
Maximum
Systolic LV pressure (mm Hg)
Preinjection
Postinjection
Heart rate (beats/min)
Preinjection
Postinjection
Dipyridamole
115 ± 17*
137 ± 17*
100 ± 8*
80 ± 9*
140 ± 12*
140 ± 12*
Control State
66 ± 117
28 ± 11*
(2 ± 1 srt
100 ± 22*
(9 ± 4 s)t
112.5 ± 12
100 ± 11*
120 ± 14*
124 ± 16
Ischemia
26 ± 6*
26 ± 6*
90 ± 12*
90 ± 12*
140 ± 14*
140 ± 14*
Values are mean ± standard deviation. *p < 0.05 relative to control; ttimc to peak change. LV = left
ventricle.
ventricular cross section that exhibited contrast-enhanced
myocardium after selective coronary artery injections (per-
fusion zone) were compared with the number of segments
exhibiting significantly reduced wall thickening (or thin-
ning) and those with abnormal myocardial contrast half-life
vales (T V2) after greater than 50% coronary artery flow
reduction. The average cross-sectional systolic wall thick-
ening was 36.3 ± 7%, and wall thickening from segment
to segment ranged from 24.6 ± 13.2 to 50.8 ± 12.1 %.
Abnormal segmental systolic wall thickening was defined
as a value outside the normal (mean ± 2 standard deviations)
variation. Coronary artery flow determined by electromag-
netic flow probe.(EM)cbrrelated well (r = 0.81, P < 0.05)
with systolic wall thickening or thinning, supporting earlier
reports (9,10). The abnormality of regional function and
myocardial echo contrast activity was determined in the
same segments relative to - 2 standard deviations from the
previously established mean of control values. The circum-
ferential extent of myocardial contrast enhancement (5.6 ±
1.0 segments) was significantly smaller than the zone of
abnormal myocardial function (6.6 ± 1.4 segments) caused
by coronary flow reduction (greater than 50%). The extent
of myocardium exhibiting significantly abnormal echo con-
trast activity (T V2) during the coronary flow reduction (3.7
± 1.7 segmerits) was found to be significantly smaller (p
< 0.05) than the above perfusion territory, outlined by echo
contrast myocardial enhancement during selective injection
before stenosis, and also smaller than the zone with abnor-
mal systolic wall thickening. No correlation of regional
systolic wall thickening versus T V2 was found over the
range of coronary artery flow studied (r = 0.36, not
significant) .
Variability of T 1/2 measurements. The interobserver,
intraobserver and injection to injection variability of T V2
measurements was studied in 60 segments. Respective T V2
correlations coefficients were 0.92, 0.86 and 0.78, with
standard error of estimates 1.4, 2.4 and 4.5 seconds, the
latter indicating substantial variability.
Discussion
Initial assessment of a myocardial contrast echo im-
aging methodology. This preliminary study examined the
feasibility of assessing coronary blood flow levels using a
computerized analysis of myocardial contrast two-dimen-
sional echographic images obtained during intracoronary
injection of a new sonicated agent featuring small micro-
bubbles (12 ± 6 /-L). The myocardial area perfused from a
coronary artery site was visualized by echo contrast en-
hancement of the myocardium in short-axis cross sections
of the mid left ventricle (1,2). Segmental videodensito-
metric myocardial contrast two-dimensional echocardio-
Table 2. Segment to Segment Variation of Myocardial Echo Contrast Washout (T '/2) in Two-Dimensional Echocardiographic Short-
Axis Left Ventricular Cross Section During Control State
Segment 2 3 4 5 6 7 8 9 10 II 12
Mean 4.9 4.6 5. I 4.7 5.0 5. I 5.1 5.5 5.6 5.5 5.0 5.6
± SD 0.8 1.0 0.8 1.0 0.9 1.3 1.2 1.2 1.4 1.0 1.1 1.3
Average for entire cross section T '/2 = 5.2 ± 3 seconds. SD = standard deviation.
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Table 3. Myocardial Contrast Echo Time-Intensity Curve Analysis at Various Levels of Coronary Artery Flow
Coronary Flow Upstroke Time to Decay Overall
(ml/min) Half-Time (sec) Peak (sec) T '/2 (sec) Duration (sec)
Hypermia 115 ± 17* 0.4 ± 0.1* 2 ± I 2 ± 2* 7 ± 3*
Control 66 ± 17* 0.8 ± 0.9 2 ± I 5.2 ± 0.3 14 ± I
Ischemia 26 ± 6 1.5 ± 0.5* 4 ± 2* 9 ± 2* 20 ± 4"
Values are in mean ± standard deviation. *p < 0.05 versus control.
graphic analysis after contrast agent administration yielded
several indexes derived from the echo intensity appearance-
disappearance curve, which allowed reliable differentiation
between ischemic, hyperemic (intravenous dipyridamole)
and control levels of coronary artery blood flow, the latter
measured independently by electromagnetic flow probe. De-
tailed analysis of the characteristic myocardial contrast two-
dimensional echocardiographic curve revealed that not only
contrast echo disappearance half-life (T I/Z) , but also time
from appearance to peak myocardial contrast intensity, curve
upstroke time and total curve duration, could satisfactorily
differentiate the widely differing control, ischemic and hy-
peremic flow levels. Stich myocardial contrast two-dimen-
sional echocardiographic analysis therefore suggests the po-
tential feasibility of characterizing sufficiently different
myocardial perfusion states.
The dynamic assessment of myocardial contrast echo
imaging was obtained concurrently with quantitative two-
dimensional echocardiographic measurements of myo-
cardial function in the same left ventricular segment. Al-
though computerized analysis of two-dimensional echo-
cardiography and myocardial contrast two-dimensional
echocardiography provided information on the extent of ab-
Figure 4. Relation between percent of coronary artery flow re-
duction ot increase from the control level and the myocardial
contrast decay phase half-life (T '/z) for the center of the ischemic
tone. Coronary artery flow reduction results in a distinct increase
in T I/z, although T '/2 decreases during dypiridamole-induced
hyperemia. Values are mean ± standard deviation. *p < 0.05
compared with control.
* II20
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normalities in cardiac function and myocardial echo contrast
washout, we were not able to show a correlation between
segmental systolic wall thickening and the echo contrast
indexes of myocardial blood flow (r = 0.36, not signifi-
cant). Myocardial contrast two-dimensional echocardio-
graphic-derived T Vz for the centrally perfusion zone cor-
related weakly with coronary artery flow (r = 0.56, P <
0.05).
Potential limitations of method. Myocardial contrast
echocardiographic applications are relatively new (1,2), and
recent studies (1,2,11-13) have not been able to meet an-
ticipated requirements for quantification of reflected echo
amplitudes associated with echo contrast passage through
the myocardial microcirculation. Specifically, there is as yet
a lack of pertinent data regarding physical properties of
myocardial contrast agents proposed for study of myocardial
perfusion or evidence that these agents will not significantly
impede or obstruct the capillary blood flow (3). Nor have
investigations (12,13) addressed the issue of ultrasound
equipment modifications required for appropriate videoden-
sitometric quantitation of reflected echo amplitudes.
Initial studies of myocardial contrast two-dimensional
echocardiography reported from this laboratory (7,14) were
aimed at detecting and outlining perfusion defects. These
studies used hand-agitated saline-Renografin echo contrast
agents containing large microbubbles (16 ± 13 11-) and
employed unmodified ultrasound equipment (2,7,14). The
difficulty of applying such an approach to quantitative as-
sessment of perfusion and coronary blood flow levels is
illustrated by the correspondingly high myocardial echo con-
trast decay T V2 values (23 ± 8 seconds) encountered with
the hand-agitated agent, significantly (p < 0.05) in excess
of values in the present sonicated agent study (5.2 ± 0.3
seconds), which approached physiologic tissue transit times
previously measured with different methods (6,15).
Our choice to analyze echo contrast dynamics from the
myocardial echo contrast time-intensity curves was made
because of the similarity between such curves and those
used with dye-dilution or thermodilution techniques (16).
Initially we examined whether the echo contrast agent was
inert, and would not by itself influence coronary blood flow.
As is evident from Table I, the particular echo contrast
agent (and others currently used or considered) induces a
significant hyperemic response in normal coronary blood
flow states. However, our pertinent myocardial contrast two-
JACC Vol. 3, No.5
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dimensional echocardiographic measurements were concen-
trated a very short period after contrast injection, during the
initial reduction in coronary blood flow and before the major
hyperemia (Fig. 3). Furthermore, the hyperemic response
was essentially absent at greater than 50% flow reduction
and was also virtually absent during injections in the setting
of intravenous dipyridamole-induced hyperemia. The hy-
peremic response is a phenomenon that will probably char-
acterize, to some extent, all the intracoronary contrast agents
considered for contrast echocardiographic or angiocardio-
graphic applications (17).
Because we fitted a monoexponential through the decay
phase of the echo contrast appearance-disappearance curve
on the basis of operator designation of a maximal and min-
imal echo contrast intensity, the potential error of such a
subjective approach must also be kept in mind. Thus, our
studies of T \/2 measurement reproducibility showed sub-
stantial injection to injection variability.
As indicated, control state T \/2 values of the current
study are significantly (p < 0.05) shorter than previous T
\/2 data from this laboratory using hand-agitated saline-Ren-
ografin solution. Yet, the present T \/2 value of 5.2 ± 0.3
seconds is still longer than a physiologically measured tissue
transit time of 2.0 ± 3.2 seconds (15), and this is presum-
ably due to the 12 ± 6 J.L microbubble size. It is thought
that all the microbubbles of 10 or more microns will at least
temporarily obstruct canine capillary flow, and thus prolong
transit.
Myocardial contrast two-dimensional echocardio-
graphic derivation of regional indexes of function and
perfusion. Echocardiography is a most sensitive and useful
technique for analysis of regional myocardial function (8, 19).
Confirming findings reported previously (8,18), measure-
ments of systolic wall thickening (in the midleft ventricular
segments) indicated a large regional variation (± 20%) in
the control state with unrestricted coronary flow. Neverthe-
less, systolic wall thickening correlated quite well with coro-
nary blood flow (r = 0.81, P < 0.05) and observations
suggest that a reduced systolic wall thickening may be a
sensitive indicator of decreased myocardial blood flow (9,10).
Our present study indicates that T \/2 and other indexes
derived from myocardial contrast appearance-disappearance
curves may serve as indexes of coronary artery flow. The
lack of correlation between regional systolic wall thickening
and T 1/2 in equivalent segments (r = 0.36, not significant)
might be related to potential errors introduced by hand in-
jecting the echo contrast agent and other factors causing
injection to injection variability. A main disadvantage of
current quantitation with contrast echocardiography is the
inability to control the quantity of microbubbles in each
injection, in a manner equivalent to controlling the mass of
dye for dye-dilution studies (16).
Potential improvements of the myocardial contrast
two-dimensional echocardiographic procedure. Future
myocardial contrast two-dimensional echocardiographic
studies should include the use of an intracoronary injection
device providing controlled pressure, flow and amount of
the injectate. Improved echo contrast agents containing small
« 7 J.L) and inert microbubbles are also needed to facilitate
capillary transit (6). Further validation and correlation in-
vestigations are required.
Echocardiographers have used echo contrast agents ex-
tensively in the past, but microbubble size within injectates
was seldom known, apparently ranged widely and there may
also have been a lack of persistence (11,14), the micro-
bubbles applied in the current study feature satisfactory re-
producibility, stability and only small variations in size,
although even smaller microbubble diameter will be needed
in the future (3). Assuming successful further developments
in this area, the potentials of the myocardial contrast two-
dimensional echocardiographic technique are considerable,
particularly in view of new computer algorithms and im-
proved ultrasound technology. Ultimately, newer echo con-
trast agents will be injected from a pulmonary artery (6) or
intravenous site, enabling simultaneous diagnostic evalua-
tion of regional myocardial function along with regional
myocardial perfusion.
Conclusion. A new myocardial contrast two-dimen-
sional echocardiographic method is described and its mea-
surements examined through experimental validation with
simultaneously measured myocardial blood flow. Reducing
coronary blood flow from a high dipyridamole-induced level
to severely ischemic states, the new method proved capable
of characterizing the extent of regional underperfusion, al-
though satisfactory quantitation of the myocardial perfusion
level is not as yet demonstrated. Several important current
limitations are discussed, including the need for improved
echo contrast agents and more advanced ultrasound tech-
nology and computer analysis. Provided these preliminary
findings can be reproduced by others and further improve-
ments made, myocardial contrast two-dimensional echo-
cardiography will constitute a useful tool for experimental
and clinical assessment of myocardial regions in terms of
their contractile function and perfusion.
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